Objectives: To evaluate the efficacy of a 1-day course of valacyclovir in reducing the duration and severity of genital herpes recurrences and to measure the frequency of viral shedding episodes ...
March 25, 2003 (San Francisco) — Final analysis of a multicenter study of 1,484 herpes simplex virus 2 (HSV-2)–discordant couples indicates that chronic valacyclovir suppressive therapy can reduce the ...
Please provide your email address to receive an email when new articles are posted on . Herpes simplex encephalitis (HSE) is likely the most serious herpes infection patients can face. Treatment ...
Low-dose suppressive valacyclovir treatment of herpes zoster ophthalmicus (HZO) did not show significant benefits at 12 months but showed treatment superiority at 18 months and a reduction in the ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Valacyclovir can be beneficial for treating multiple episodes of keratitis or iritis in patients with ...
In a study appearing in the December 20 issue of JAMA, Anna Wald, M.D., M.P.H., of the University of Washington & Fred Hutchinson Cancer Research Center, Seattle, and colleagues compared the ...
NEW YORK (Reuters Health) - Recurrent outbreaks of herpes simplex virus 2 (HSV2), or "genital herpes," can be effectively treated with a one-day course of valacyclovir (sold under the trade name ...
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat ...
Significant treatment benefits seen at 18 months; in addition, risk for experiencing subsequent end points lower with valacyclovir. HealthDay News — One year of valacyclovir is beneficial for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback